A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells

In this study, a simplified, scalable, robust, and integrated differentiation platform was developed to generate clinical grade hPSC-CMs as cell aggregates under chemically defined culture conditions. This approach resulted in approximately 100% beating CM spheroids with virtually pure (~90%) functional cardiomyocytes in 10 days from multiple hPSC lines. This universal and robust bioprocessing platform can provide sufficient numbers of hPSC-CMs for companies developing regenerative medicine technologies to rescue, replace, and help repair damaged heart tissues and for pharmaceutical companies developing advanced biologics and drugs for regeneration of lost heart tissue using high-throughput technologies. It is believed that this technology can expedite clinical progress in these areas to achieve a meaningful impact on improving clinical outcomes, cost of care, and quality of life for those patients disabled and experiencing heart disease.

Source: Stem Cells Translational Medicine - December 10, 2015 Category: Stem Cells Authors: Fonoudi, H., Ansari, H., Abbasalizadeh, S., Larijani, M. R., Kiani, S., Hashemizadeh, S., Zarchi, A. S., Bosman, A., Blue, G. M., Pahlavan, S., Perry, M., Orr, Y., Mayorchak, Y., Vandenberg, J., Talkhabi, M., Winlaw, D. S., Harvey, R. P., Aghdami, N., Bah Tags: Protocols and Manufacturing for Cell-Based Therapies, Pluripotent Stem Cells Source Type: research